Health Innovation Next Generation Payment & Pricing Models

Informacje na temat projektu

HI-PRIX

Identyfikator umowy o grant: 101095593

DOI

10.3030/101095593

Projekt został zamknięty

Data podpisania przez KE 11 Listopada 2022

Data rozpoczęcia 1 Stycznia 2023

Data zakończenia 31 Grudnia 2025

Finansowanie w ramach

• Health

Koszt całkowity

€ 3 962 457,50

Wkład UE

€ 3 962 457,50

Koordynowany przez

UNIVERSITA COMMERCIALE LUIGI BOCCONI
Italy

CORDIS oferuje możliwość skorzystania z odnośników do publicznie dostępnych publikacji i rezultatów projektów realizowanych w ramach programów ramowych HORYZONT.

Odnośniki do rezultatów i publikacji związanych z poszczególnymi projektami 7PR, a także odnośniki do niektórych konkretnych kategorii wyników, takich jak zbiory danych i oprogramowanie, są dynamicznie pobierane z systemu OpenAIRE .

Rezultaty

Documents, reports (13)

Recommendations on pricing principles for multi-indication products and conditions for their successful implementation
A novel dynamic pricing model that links to clinical benefit: impact and acceptability for stakeholders
Strength of incentive mechanisms and policy recommendations to incentivize pharmaceutical innovation in key areas of need
Equity implications of including indirect medical costs and environmental impacts in economic evaluations informing pricing and reimbursement
Policy guide on the role of cost-effectiveness and budget impact analyses (including indirect medical costs and environmental impacts) in pricing and reimbursement decisions in different European decision contexts
Outline of the equity-issues mitigation strategies identified, and related potential obstacles
Stakeholders judgement on barriers and enablers of novel payment/pricing schemes
Effectiveness and equity implications of selected pharmaceutical innovation policies and incentive mechanisms
Guidance (Handbook) on estimations (ranges) of cost elements along the value chain for demanding detailed information in price negotiations
Report on the overall performance of a selection of equity-issues mitigation strategies and recommendations
Set of recommendations for using the public investment in the negotiation/HTA process and pilot example how price can be different if public investment is considered
Policy recommendations about successful and flexible implementation of the different schemes to promote access to high-quality affordable innovative health technologies
Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on lo

Report on contextualization of simulation results and synthesis of findings with regard to the current use and the regulatory measures, levers and barriers to the widespread practical implementation of the respective payment schemes and their impact on long-term competition in health technology markets

Demonstrators, pilots, prototypes (2)

Assessment of transferability and generalizability of results and development of a toolkit for decision-makers
Impact of applying the new payment schemes to (a) a primary care and (b) an integrated care setting

Websites, patent fillings, videos etc. (1)

Launch of project website

Publikacje

Peer reviewed articles (18)

Early and accelerated access programs for medical devices in the European Union: mapping regulatory derogations and national schemes

Autorzy: Baptiste Haon, Mira Hartmann, Sanae Akodad, Hilde Stevens, Lise Rochaix
Opublikowane w: Frontiers in Medical Technology, Numer 8, 2026, ISSN 2673-3129
Wydawca: Frontiers Media SA
DOI: 10.3389/FMEDT.2026.1729631

Journal of Pharmaceutical Policy and Practice

Autorzy: Louise Schmidt; Ozren Sehic; Ursula Theuretzbacher; Daniel Fabian; Claudia Wild
Opublikowane w: Journal of Pharmaceutical Policy and Practice, 2025, ISSN 2052-3211
Wydawca: Taylor & Francis
DOI: 10.1080/20523211.2024.2449045

AIHTA-Framework erleichtert Identifikation öffentlicher Beiträge zur Entwicklung von Innovationen im Gesundheitswesen

Autorzy: Ozren Sehic
Opublikowane w: QUALITAS, 2024, ISSN 2730-7298
Wydawca: Springer Nature
DOI: 10.1007/S43831-024-0187-6

Mechanisms Considering Public Investment in Pricing and Reimbursement Decisions of Medicines and Other Health Technologies: A Scoping Review

Autorzy: Mario García-Díaz; Zuzana Špacírová; Leticia García-Mochón; Jaime Espín
Opublikowane w: Applied Health Economics and Health Policy, 2025, ISSN 2509-4254
Wydawca: Springer Nature
DOI: 10.1007/S40258-025-00994-5

Frontiers in Psychiatry

Autorzy: Sanae Akodad, Michel Goldman, Hilde Stevens
Opublikowane w: Frontiers in Medicine, Numer 12, 2025, ISSN 1664-0640
Wydawca: Frontiers Research Foundation
DOI: 10.3389/FMED.2025.1642882

Applied Health Economics and Health Policy

Autorzy: Ludovico Cavallaro; Vittoria Ardito; Michael Drummond; Oriana Ciani
Opublikowane w: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Wydawca: Open Mind Journals
DOI: 10.1007/S40258-025-00963-Y

Health Policy

Autorzy: Claudia Wild; Ozren Sehic; Louise Schmidt; Daniel Fabian
Opublikowane w: Health Policy, 2025, ISSN 0168-8510
Wydawca: Elsevier Ltd.
DOI: 10.1016/J.HEALTHPOL.2024.105235

Frontiers in Pharmacology

Autorzy: García Díaz, Mario; Epstein, David Mark; Espín, Jaime
Opublikowane w: Frontiers in Pharmacology, 2025, ISSN 1663-9812
Wydawca: Frontiers Media SA
DOI: 10.3389/FPHAR.2025.1670845

Social Science and Medicine

Autorzy: Arianna Gentilini; Marisa Miraldo
Opublikowane w: Social Science & Medicine, 2023, ISSN 0277-9536
Wydawca: Pergamon Press Ltd.
DOI: 10.1016/J.SOCSCIMED.2023.116332

Orphan medical devices: addressing the regulatory and access gaps in the EU and US

Autorzy: Sanae Akodad; Baptiste Haon; Lise Rochaix; Hilde Stevens
Opublikowane w: Frontiers in Public Health, 2026, ISSN 2296-2565
Wydawca: Frontiers Media SA
DOI: 10.3389/FPUBH.2025.1729821

Transferable Exclusivity Extension Vouchers for Antimicrobials: Incentive Design, Implementation Challenges, and Policy Trade-Offs

Autorzy: Mario García-Díaz; Jorge Mestre-Ferrándiz; Jaime Espín
Opublikowane w: PharmacoEconomics - Open, 2026, ISSN 2509-4262
Wydawca: Springer Nature
DOI: 10.1007/S41669-025-00628-5

PharmacoEconomics

Autorzy: Vittoria Ardito; Oriana Ciani; Michael Drummond
Opublikowane w: PharmacoEconomics, 2024, ISSN 1179-2027
Wydawca: Adis International Ltd.
DOI: 10.1007/S40273-024-01435-2

Applied Health Economics and Health Policy

Autorzy: Ardito, Vittoria; Banks, Helen; Tarricone, Rosanna
Opublikowane w: Applied Health Economics and Health Policy, 2025, ISSN 1175-5652
Wydawca: Springer Nature
DOI: 10.1007/S40258-025-01010-6

Journal of Pharmaceutical Policy and Practice

Autorzy: Daniel Fabian; Ozren Sehic; Claudia Wild
Opublikowane w: The origins of Novo Nordisk and Novartis products: piloting a framework to identify the public contributions, 2025, ISSN 2052-3211
Wydawca: Taylor & Francis Group
DOI: 10.1080/20523211.2025.2534919

Medicare Negotiations Could Fuel, Not Stifle, Innovation.

Autorzy: Chuanzi Yue, Marisa Miraldo
Opublikowane w: Health Affairs Forefront, 2025, ISSN 3070-667X
Wydawca: Health Affairs Publishing, LLC
DOI: 10.1377/FOREFRONT.20250116.482319

A Framework for Considering the Role of the Public Sector in R&D of Health Technology

Autorzy: Juan Carlos Rejon-Parrilla; David Epstein; Jorge Mestre-Ferrandiz; Jaime Espin
Opublikowane w: Pharmaceutical Medicine, 2025, ISSN 0306-3747
Wydawca: Springer Nature
DOI: 10.1007/S40290-025-00576-9

Mapping Payment and Pricing Schemes for Health Innovation: Protocol of a Scoping Literature Review

Autorzy: ARDITO, VITTORIA; CAVALLARO, LUDOVICO; DRUMMOND, MICHAEL; CIANI, ORIANA
Opublikowane w: PharmacoEconomics - Open, 2024, ISSN 2509-4254
Wydawca: Springer Nature
DOI: 10.1007/S41669-024-00496-5

ESG Performance, Debt Financing, and R&D Output: Evidence From the Healthcare Sector

Autorzy: Sarmad Ali; Oriana Ciani; Simone Ghislandi
Opublikowane w: Business Strategy and the Environment, ISSN 1099-0836
Wydawca: John Wiley & Sons Ltd
DOI: 10.1002/BSE.70522